S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Are We in a Bear Market? Here are the Signs
2 Dollar Stores Taking Different Paths to Profitability
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Are We in a Bear Market? Here are the Signs
2 Dollar Stores Taking Different Paths to Profitability
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Are We in a Bear Market? Here are the Signs
2 Dollar Stores Taking Different Paths to Profitability
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Are We in a Bear Market? Here are the Signs
2 Dollar Stores Taking Different Paths to Profitability
NASDAQ:AKTX

Akari Therapeutics (AKTX) Stock Price, News & Analysis

$2.00
+0.03 (+1.52%)
(As of 03/18/2024 ET)
Today's Range
$1.97
$2.00
50-Day Range
$1.97
$3.01
52-Week Range
$1.95
$5.72
Volume
1,859 shs
Average Volume
9,027 shs
Market Capitalization
$11.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
AKTX stock logo

About Akari Therapeutics Stock (NASDAQ:AKTX)

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

AKTX Stock Price History

AKTX Stock News Headlines

Akari Therapeutics, Plc (NASDAQ:AKTX) Short Interest Update
AI Cracks Open Largest Untapped Energy Reserve on Earth
This orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… 
The AI Bottleneck No One is Talking About
Renewable energy is growing at an impressive speed - but not fast enough. This could be one of the greatest periods for the nuclear industry ever.
Akari Therapeutics PLC (AKTX)
Akari Therapeutics to Present at Biotech Showcase 2024
Akari Therapeutics (AKTX) Earnings Dates & Reports
Akari Therapeutics, Plc (CLA.F)
See More Headlines
Receive AKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/31/2020
Today
3/18/2024
Next Earnings (Estimated)
5/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AKTX
Employees
15
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.48 per share

Miscellaneous

Free Float
2,159,000
Market Cap
$11.30 million
Optionable
Not Optionable
Beta
1.02
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Ms. Rachelle Suzanne Jacques (Age 53)
    President, CEO & Director
    Comp: $1.38M
  • Ms. Wendy F. DiCicco CPA (Age 57)
    Interim Chief Financial Officer
  • Ms. Melissa Bradford-Klug (Age 54)
    Chief Operating Officer
  • Dr. Miles Nunn (Age 55)
    Chief Scientific Officer
  • Dr. John F. Neylan III (Age 71)
    M.D., Executive VP & Chief Medical Officer
  • Ms. Beth-Anne Lang
    Senior Vice President of Regulatory Affairs
  • Annie Mack
    Financial Controller

AKTX Stock Analysis - Frequently Asked Questions

How have AKTX shares performed in 2024?

Akari Therapeutics' stock was trading at $3.12 on January 1st, 2024. Since then, AKTX shares have decreased by 35.9% and is now trading at $1.9999.
View the best growth stocks for 2024 here
.

Are investors shorting Akari Therapeutics?

Akari Therapeutics saw a increase in short interest during the month of February. As of February 29th, there was short interest totaling 9,600 shares, an increase of 10.3% from the February 14th total of 8,700 shares. Based on an average daily trading volume, of 8,700 shares, the days-to-cover ratio is currently 1.1 days. Currently, 0.2% of the company's stock are short sold.
View Akari Therapeutics' Short Interest
.

When is Akari Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our AKTX earnings forecast
.

How were Akari Therapeutics' earnings last quarter?

Akari Therapeutics, Plc (NASDAQ:AKTX) announced its quarterly earnings results on Tuesday, March, 31st. The biopharmaceutical company reported ($7.80) EPS for the quarter, missing analysts' consensus estimates of ($2.80) by $5.00.

When did Akari Therapeutics' stock split?

Akari Therapeutics shares reverse split on Thursday, August 17th 2023. The 1-20 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Akari Therapeutics own?
Who are Akari Therapeutics' major shareholders?

Akari Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Omnia Family Wealth LLC (1.55%).
View institutional ownership trends
.

How do I buy shares of Akari Therapeutics?

Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AKTX) was last updated on 3/19/2024 by MarketBeat.com Staff

From Our Partners